Online inquiry

IVTScrip™ mRNA-Anti-ICOS, JTX-2011(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9829MR)

This product GTTS-WQ9829MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets ICOS gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_012092.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 29851
UniProt ID Q9Y6W8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ICOS, JTX-2011(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ9829MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11265MR IVTScrip™ mRNA-Anti-CD274, MEDI4736(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MEDI4736
GTTS-WQ11868MR IVTScrip™ mRNA-Anti-GUCY2C, MLN-0264(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MLN-0264
GTTS-WQ2861MR IVTScrip™ mRNA-Anti-ICOS, AMG-570(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG-570
GTTS-WQ11582MR IVTScrip™ mRNA-Anti-ERBB2, MGAH-22(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MGAH-22
GTTS-WQ6461MR IVTScrip™ mRNA-Anti-HA, CT-P23(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CT-P23
GTTS-WQ7945MR IVTScrip™ mRNA-Anti-ICOS, GSK-3359609(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA GSK-3359609
GTTS-WQ6702MR IVTScrip™ mRNA-Anti-SLC34A2, DNIB0600A(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA DNIB0600A
GTTS-WQ4147MR IVTScrip™ mRNA-Anti-PDCD1, BI-754091(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BI-754091
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW